Investor Alert: Pomerantz Law Firm Investigates NovoCure Limited for Potential Securities Fraud
The Pomerantz Law Firm is investigating potential securities fraud by NovoCure and its officers following the release of disappointing Phase 3 clinical trial results. The stock price dropped significantly after announcing that the Early Start Arm did not show a statistically significant improvement in overall survival compared to the Maintenance Start Arm.
Tickers: $NVCR
Topics: class action clinical trial results investor claims stock price drop